Fluxus is a leader in optofluidics that provides systems and solutions to advance the detection, diagnosis, monitoring, and treatment of disease. Our expertise lies at the interface of advanced photonics, engineering, chip fabrication, assay development, and reagent manufacturing excellence.

We seek to close a major gap in clinical research and diagnostics by bringing our groundbreaking ultrasensitive detection technologies and assay solutions to researchers, clinicians, patients, and key industry players through strong partnerships and a future-proof portfolio of innovative products.

Fluxus was founded in 2016 and acquired in 2022 by Fujirebio Holdings, Inc., an R&D-driven company constantly developing new IVD technologies and unique biomarkers with high clinical value.

Today, as a wholly-owned subsidiary of Fujirebio, Fluxus represents a unique blend of Silicon Valley startup ingenuity with the stability and reach of an established multinational corporation. Our experienced, multidisciplinary team draws on deep and varied expertise to continuously innovate and drive towards our goal of becoming the gold standard in single-molecule counting and ultrasensitive biomolecular testing.